Study of NNZ-2591-PMS-301 in Pediatric Participants with Phelan McDermid Syndrome

A Phase 3 Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Orally Administered NNZ-2591-PMS-301 Compared with Placebo in Pediatric Participants with Phelan McDermid Syndrome

Help research for Phelan-McDermid Syndrome reach new heights.

Consider the Koala clinical study, exploring an investigational treatment that may potentially improve symptoms in children with Phelan-McDermid Syndrome.

Currently, there are no treatments for Phelan-McDermid Syndrome. The Koala study is evaluating an investigational treatment in children with the condition to see if it improves how they feel and function. The study is expected to last about 19 weeks for each child.

This study is enrolling children 3 to 12 years of age who:

• Have been diagnosed with Phelan-McDermid Syndrome
• Have had their diagnosis confirmed by genetic testing
• Weigh at least 10 kg (22 lbs)